Phaseline

Targets › AKR1C3

AKR1C3 (Aldo-keto reductase family 1 member C3): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Oct 2027.

Cytosolic aldo-keto reductase that catalyzes NADPH-dependent reduction of ketosteroids to hydroxysteroids. Displays broad substrate specificity with distinct positional and stereochemistry, primarily generating 17beta-hydroxysteroids, but also 3alpha- and 20alpha-hydroxysteroids. (UniProt, P42330)

Open in Phaseline: the race on AKR1C3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Zhejiang Hisun PharmaceuticalAST-3424
AKR1C3 inhibitor
AKR1C3Phase 2HCC - Hepatocellular CarcinomaOct 2027
SWOG Cancer Research NetworkOBI-3424
AKR1C3-activated prodrug
AKR1C3Phase 1Recurrent T Acute Lymphoblastic LeukemiaAug 2028

Conditions

Recurrent T Acute Lymphoblastic Leukemia (1) HCC - Hepatocellular Carcinoma (1)

Modalities

protein or peptide (1), small molecule (1)

Companies

SWOG Cancer Research Network (1) Zhejiang Hisun Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.